| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | aur |
| Uniprot No | D7UQM5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-407aa |
| 氨基酸序列 | MTPTGPSHHS MAPKRVLPAA SQSNMYGNIR SASTTSTTAS TSSQALRLLQ NAKTSKNADN RIAHAERQGP PSAHPAAMQK PAARVAPSNE NRPDPAARQH QHQQQLQQQK ATGHDRVLKE SQAGNSTTTT MTSTQSKEAN KWSLANFDIG RPLGKGKFGN VYLAREKKSK FIVALKVLFK SQLQKAKVEH QLRREIEIQS HLRHDHILRL YGYFYDDTRV YLILEYAARG ELYKEMQAQK AGHFDEDRSA VYIYQLAKAL LYCHEKKVIH RDIKPENLLL DLKGDLKIAD FGWSVHAPSS RRATLCGTLD YLPPEMIEGK THDEKVDLWS LGVLCYEFLV GKPPFESQGN TETYRKITKV EFTFPKHVSE GARDLICKLL KHNPSHRLSL EGVIAHAWIQ EKISQRS |
| 预测分子量 | 45,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Aur(Aurora激酶)重组蛋白研究的模拟参考文献示例(文献信息为虚构，仅供格式参考)：
1. **《Structural analysis of recombinant Aurora A kinase for cancer drug screening》**
*作者：Smith J, et al. (2020)*
摘要：研究通过大肠杆菌系统表达重组Aurora A激酶，解析其晶体结构并验证其酶活性，为高通量抗癌药物筛选提供工具。
2. **《Optimization of recombinant Aurora B expression in mammalian cells》**
*作者：Wang L, et al. (2018)*
摘要：通过密码子优化和培养条件改进，在HEK293细胞中实现Aurora B重组蛋白高效表达，并验证其在细胞周期调控中的功能。
3. **《Functional characterization of Aurora kinase mutants in chromosomal instability》**
*作者：Garcia R, et al. (2019)*
摘要：利用重组Aurora C突变体蛋白研究其与微管结合异常的关系，揭示该激酶在减数分裂错误中的分子机制。
4. **《Recombinant Aurora kinase inhibitors in triple-negative breast cancer models》**
*作者：Chen X, et al. (2021)*
摘要：基于重组Aurora A蛋白筛选小分子抑制剂，在动物模型中显示其可显著抑制三阴性乳腺癌的转移活性。
---
**说明**：
- 以上文献为示例，实际研究需检索真实数据库(如PubMed、Web of Science)。
- 建议检索关键词：**"Aurora kinase recombinant expression"、"Aurora protein purification"**。
- Aurora激酶家族(Aurora A/B/C)是肿瘤治疗的热门靶点，相关重组蛋白研究多聚焦于药物开发与机制解析。
Aurora kinases are a family of serine/threonine kinases essential for regulating mitotic progression, particularly in spindle assembly, centrosome maturation, and chromosome segregation. Three isoforms (AURKA, AURKB, AURKC) exist in humans, with AURKA and AURKB being widely studied due to their roles in cell cycle control and oncogenesis. Overexpression or mutations in Aurora kinases are linked to genomic instability and cancer, making them attractive therapeutic targets.
Recombinant Aurora proteins are engineered versions produced via heterologous expression systems (e.g., E. coli, insect, or mammalian cells) to study their biochemical properties, structure, and interactions. These proteins retain catalytic activity and are pivotal for in vitro assays, inhibitor screening, and structural studies (e.g., X-ray crystallography). Recombinant technology allows post-translational modifications (e.g., phosphorylation) critical for kinase activation, enabling researchers to mimic native protein behavior.
The development of Aurora kinase inhibitors—many derived from studies using recombinant proteins—has been a focus in oncology. However, clinical success has been limited due to off-target effects and acquired resistance. Current research emphasizes isoform-specific inhibitors and combination therapies. Recombinant Aurora proteins also aid in identifying biomarkers for patient stratification and monitoring drug efficacy.
Beyond cancer, Aurora kinases are implicated in non-mitotic processes (e.g., ciliogenesis, neuronal development), expanding their therapeutic relevance. Advances in protein engineering, such as cryo-EM and mutagenesis, continue to refine Aurora kinase models, aiding drug design. Despite challenges, recombinant Aurora proteins remain indispensable tools for deciphering mitotic mechanisms and accelerating targeted cancer therapies.
×
